facilities_lg06

Indivior launches authorised generic version of opioid addiction treatment Suboxone as rival generic drugmakers enter market

pharmafile | February 21, 2019 | News story | Sales and Marketing Alvogen, Dr Reddy's, Novartis, Sandoz, indivior 

Indivior has announced the launch of an authorised generic version of Suboxone Film (buprenorphine/naloxone) a combination medicine used to treat opioid use disorder, following a US court’s decision to open the market to generic competitors.

Novartis’ Sandoz unit will begin marketing the generic opioid use treatment in the US immediately.

English firm, Indivior has been battling generic drugmakers in trying to prevent Suboxone generics from entering the market for years.

Advertisement

Indivior’s stocks plummeted in November after a Washington court lifted a preliminary injunction on Dr Reddy’s which blocked the Indian firm from entering the Suboxone market.

Suboxone film accounts for 98% of Invidior’s US revenue. “An entire business, and the jobs and livelihoods that depend on it, will be in peril,” Invidior said.

Generic versions of the treatment could see Invidior lose as much as 80% of its market share within months.

The news comes as Alvogen announced the launch of its generic version of Suboxone.

Lisa Graver, President of Alvogen Americas, commented: “We are excited to launch this important product that will empower patients suffering from opioid dependence. The launch demonstrates a significant commitment from our teams to bringing affordable generic medicines to the market.”

Louis Goss

Related Content

Sandoz launches two new bone disease biosimilars in Europe

Sandoz has announced the European launch of two new bone disease biosimilars. Wyost (denosumab 120 …

Novartis receives SMC approval for early breast cancer treatment

Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval …

drug-trials

Novartis candidate for Sjögren’s disease presents positive results

Novartis has reported positive results from two phase 3 clinical trials – NEPTUNUS-1 and NEPTUNUS-2 …

The Gateway to Local Adoption Series

Latest content